News
Capital Market on MSN14h
Sun Pharma drops as foreign broker downgrades on valuation, execution risks
The broker cited stretched valuations and slower-than-expected traction in speciality drugs. It flagged concerns around ...
Sun Pharmaceutical Industries Ltd. 524715 shares inched up 0.20% to 1,642.90 Indian rupees Friday, on what proved to be an ...
Indian stock market indices Sensex and Nifty plunged significantly due to concerns over US tariffs and foreign fund outflows, ...
Bank of America downgraded Sun Pharma stock to ‘underperform’ from ‘neutral’, citing risks to premium valuations and slower ...
14don MSN
A Giant Indian Drugmaker Failed to Fix Safety Breaches. The FDA Let It Off the Hook Again and Again.
Documents obtained by ProPublica offer a rare glimpse into discussions between the global drugmaker Sun Pharma and the FDA, ...
Alembic, Sun and Glenmark issue US drug recalls due to the presence of carcinogens or foreign matter
A trio of Indian drugmakers—Alembic Pharmaceuticals, Sun Pharmaceutical and Glenmark Pharmaceuticals—issued separate ...
BoFA values the stock at 32 times FY27 earnings against its 10-year average of 25.5 times, reflecting its transition to ...
Sun Pharmaceutical shares dropped by 2.8% after Bank of America downgraded the stock due to concerns over premium valuations and slower speciality execution.
Sun Pharmaceutical Industries Ltd. closed 17.04% short of its 52-week high of 1,960.20 rupees, which the company reached on ...
Marketing Sun Pharma brightens up Ilumya promos with psoriasis campaign encouraging self-love By Andrea Park Jun 6, 2024 9:20am Ilumya Sun Pharmaceutical psoriasis DTC advertising ...
At the current price, shares of Sun Pharma are trading at a financial year 2027 price-to-earnings multiple of 32 times, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback